100 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
14 Dec 12
Other Events
12:00am
new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA … women and assessed the safety and efficacy of BZA/CE for the treatment of moderate-to-severe VMS and VVA associated with menopause, as well
8-K
EX-99.2
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Mar 09
Important Notice Concerning Limitations on Your
12:00am
-menopausal women at increased risk of fracture. FABLYN was submitted for approval in Europe in January 2008. This is the first regulatory approval … , the FDA’s Advisory Committee for Reproductive Health Drugs voted 9-3 (with one abstention) that there is a population of postmenopausal women
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
6 May 09
Ligand Pharmaceuticals Announces First Quarter Results
12:00am
estrogen receptor modulator (SERM) for the treatment of osteoporosis in post-menopausal women at increased risk of fracture. As a result of the European … -menopausal women at increased risk of fracture. As a result of the first approval of FABLYN in a major market, Ligand earned a $3 million milestone
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
24 Jul 13
Ligand Signs License Agreement with Ethicor for Oral Lasofoxifene
12:00am
. In the European Union, there are approximately 37 million women suffering with osteoporosis.
“This agreement with Ethicor represents another potentially … of Ligand. “Osteoporosis represents a large unmet medical need for women, and we are pleased that lasofoxifene could potentially provide women
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
11 May 09
Results of Operations and Financial Condition
12:00am
receptor modulator (SERM) for the treatment of osteoporosis in post-menopausal women at increased risk of fracture. As a result of the European approval … women at increased risk of fracture. As a result of the first approval of FABLYN in a major market, Ligand earned a milestone that Pfizer elected
8-K
EX-99.1
jnx2 voi5xn4
11 Oct 11
Entry into a Material Definitive Agreement
12:00am
8-K
cddv6htfibar4 6xm
27 Mar 09
Important Notice Concerning Limitations on Your
12:00am
8-K
EX-99.1
5q1wnu40b
27 Oct 14
Ligand Reports Third Quarter 2014 Financial Results
12:00am
8-K
EX-99.1
80fwk6v2xs
8 Aug 12
Ligand Pharmaceuticals Announces Second Quarter Results
12:00am
8-K
EX-99.1
nfg6kctrr
9 Feb 09
Regulation FD Disclosure
12:00am
8-K
23u 6f40jh0
18 May 10
Other Events
12:00am
CORRESP
m049875lone jm33jq
3 Jan 14
Correspondence with SEC
12:00am
425
hmifns
6 Nov 08
Business combination disclosure
12:00am
8-K
EX-99.1
f0df58e zh72r7
13 Feb 09
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results
12:00am
8-K
EX-99.1
v91yq94 plrztq04
22 Jul 13
Ligand Signs Global License Agreement with Azure for Lasofoxifene
12:00am
8-K
ufd8mnapv9l8 73
13 Oct 11
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
12:00am
8-K
EX-99.1
jlixt33c
18 Nov 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
3o7m oxwq6eqump5r1xj
14 Dec 99
Current report
12:00am
8-K
EX-99.1
pqec8q7woh
3 Aug 09
Ligand Pharmaceuticals Announces Second Quarter Results
12:00am
8-K
EX-99.1
0dvigba71 x3aa
8 Nov 11
Ligand Pharmaceuticals Announces Third Quarter Results
12:00am